{"nctId":"NCT03430856","briefTitle":"Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients","startDateStruct":{"date":"2017-12-26","type":"ACTUAL"},"conditions":["Type2 Diabetes Mellitus"],"count":143,"armGroups":[{"label":"Insulin Tregopil (IN-105) - 45mg","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin Tregopil"]},{"label":"Insulin Tregopil (IN-105) - 30mg","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin Tregopil"]},{"label":"Insulin Aspart","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Aspart"]}],"interventions":[{"name":"Insulin Tregopil","otherNames":["IN-105"]},{"name":"Insulin Aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria\n\n* Patients with an established diagnosis of T2DM and a duration of diabetes mellitus of at least 6 months at Screening based on criteria given below as per American Diabetes Association (ADA) 2017 guidelines: i. HbA1c ≥ 6.5% OR ii. FPG ≥ 126 mg/dL. (Fasting is defined as no caloric intake for at least 8 hours.) OR iii. 2-hour prandial glucose (PG) level of ≥ 200 mg/dL during an oral glucose tolerance test (OGTT).\n* Stable dose of metformin (at least 1500 mg daily \\[daily dose of at least 1000 mg is permitted if intolerant to 1500 mg dose\\]) for a period of at least 3 months prior to Screening\n* Eligible for initiation of or already receiving insulin glargine\n* Hemoglobin ≥ 10.0 g/Dl\n* HbA1c of 7.5% to 10.0 %\n* Body mass index of 18.5 to 35.0 kg/m2\n\nKey Exclusion Criteria\n\n* Patients with T1DM\n* Treatment with glucagon-like peptide 1 agonists within 12 weeks prior to Screening\n* Ongoing treatment with OADs (eg, Thiazolidinediones) contraindicated or unapproved for combination treatment with insulin\n* Presence of gastrointestinal (GI) disorders or conditions known to significantly alter the absorption of orally administered drugs or significantly alter upper GI or pancreatic function\n* History of ≥2 episodes of severe hypoglycemia (as per ADA 2017) within the 6 months before Screening\n* History of \\> 1 episode of hyperglycemic hyperosmolar coma or hospitalization for uncontrolled diabetes (eg, diabetic ketoacidosis); within the 6 months prior to Screening\n* Clinically significant cardiovascular and/or cerebrovascular disease within 12 months before Screening including, but not limited to unstable angina, myocardial infarction, Class III or Class IV congestive heart failure according to the New York Heart Association criteria, valvular heart disease, cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, coronary angioplasty, stroke or transient ischemic attack.\n* Patients with the following secondary complications of diabetes:\n\n  i. Active proliferative retinopathy as confirmed by a dilated ophthalmoscopy (by the investigator, site ophthalmologist or an optometrist; as per standard site practice) within 6 months prior to Screening. ii. Renal dysfunction indicated by modification of diet in renal disease estimated glomerular filtration rate \\< 45 mL/min/1.73 m2 and/or diabetic nephropathy and/or clinical nephrotic syndrome at Screening. iii. History or presence of severe form of neuropathy or signs and symptoms of severe cardiac autonomic neuropathy. iv. Patients with non-traumatic amputation (at any time) or clinically significant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at 24 Weeks (Part 1)","description":"The primary endpoint is change from baseline in HbA1c after 24 weeks of randomized treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.23","spread":"0.577"},{"groupId":"OG001","value":"8.10","spread":"0.670"},{"groupId":"OG002","value":"8.07","spread":"0.697"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.38","spread":"1.139"},{"groupId":"OG001","value":"8.21","spread":"0.969"},{"groupId":"OG002","value":"7.29","spread":"0.788"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 12 (Part 1)","description":"This secondary outcome is the change from baseline in HbA1c after 12 weeks of randomized treatment. For this endpoint baseline (Week 0) and Week 12 have been presented.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.23","spread":"0.577"},{"groupId":"OG001","value":"8.10","spread":"0.670"},{"groupId":"OG002","value":"8.07","spread":"0.697"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.04","spread":"0.940"},{"groupId":"OG001","value":"8.01","spread":"0.898"},{"groupId":"OG002","value":"7.18","spread":"0.810"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.913"},{"groupId":"OG001","value":"-0.07","spread":"0.866"},{"groupId":"OG002","value":"-0.88","spread":"0.850"}]}]}]},{"type":"SECONDARY","title":"Participants Achieving HbA1c < 7% (Part 1)","description":"Number of participants achieving HbA1c \\< 7% at Week 12 and Week 24.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hypoglycemia Events During 24-week Treatment Period (Part 1)","description":"A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose concentration of ≤ 70 milligrams/deciliter \\[mg/dL (3.9 millimoles/liter (mmol/L)\\]","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight (Kgs) (Part 1)","description":"Change from Baseline in weight (kgs) to 24 weeks","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.54","spread":"11.559"},{"groupId":"OG001","value":"68.88","spread":"9.040"},{"groupId":"OG002","value":"67.76","spread":"9.628"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.98","spread":"11.837"},{"groupId":"OG001","value":"70.15","spread":"8.915"},{"groupId":"OG002","value":"68.47","spread":"9.761"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"1.212"},{"groupId":"OG001","value":"0.30","spread":"1.955"},{"groupId":"OG002","value":"0.66","spread":"1.807"}]}]}]},{"type":"SECONDARY","title":"Lipid Profile (Part 1)","description":"Change from Baseline in lipid profile (triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol) to 24 weeks","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Post-prandial Glucose (PPG) Excursion (Part 1)","description":"Change from Baseline in the mean 60, 90, 120 minutes PPG excursions assessed from standardized test meal at Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":"45.53"},{"groupId":"OG001","value":"98.3","spread":"41.94"},{"groupId":"OG002","value":"74.4","spread":"42.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":"47.94"},{"groupId":"OG001","value":"106.4","spread":"35.39"},{"groupId":"OG002","value":"90.8","spread":"35.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.9","spread":"58.18"},{"groupId":"OG001","value":"113.5","spread":"53.45"},{"groupId":"OG002","value":"93.7","spread":"41.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":"44.26"},{"groupId":"OG001","value":"32.7","spread":"45.13"},{"groupId":"OG002","value":"55.1","spread":"34.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":"45.38"},{"groupId":"OG001","value":"47.2","spread":"44.84"},{"groupId":"OG002","value":"66.3","spread":"36.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":"51.87"},{"groupId":"OG001","value":"50.2","spread":"44.23"},{"groupId":"OG002","value":"65.5","spread":"34.58"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (Part 1)","description":"Includes participants who have experienced at least one treatment emergent adverse events over 24 weeks","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-drug Antibody Levels","description":"Incidence and change from baseline in the relative levels of anti-drug antibody levels over 24 weeks","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"CGM","description":"Area under the glucose curve below 70 mg/dL derived from CGM, applicable for only part II study","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24","description":"Number of participants achieving HbA1c \\< 7% at Week 12 and Week 24 without reported clinically significant or severe hypoglycemic events between end of Week 8 and Week 24.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Gastritis","Pyrexia","Nausea","Pain","Urinary tract infection"]}}}